For More Information:
I joined University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) in 2004 following a 20-year career in the U.S. Public Health Service. For the last 10 years of my Federal career, I served as Associate Director of the Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program, which is the pre-clinical cancer treatment drug and biological discovery and development program of the National Cancer Institute (NCI). In that capacity, I managed project flow and quality of output monitoring for Federal research ($31-$52 million per year) and development contracts with 400-500 employees. Under my leadership, more than 60,000 new molecular entities were evaluated in NCI screens, and more than 30 agents passed into clinical trials under NCI sponsorship, including the molecule now known as Velcade -- originally emerging in part from an NCI screening collaboration with ProScript, and which is FDA approved for multiple myeloma. I became the director of the Clinical Research Shared Service and associate director for Clinical Research at UMGCC in 2004.
I am responsible for having implemented the Oncore electronic database for use across the UMGCC's protocol management system and restructuring UMGCC's Data Safety Monitoring process for addressing adverse event reporting and synchronizing with IRB review across all protocols. I also chair the Data Safety Monitoring Board for NCI's National Lung Tumor Screening Study, which enrolls more than 50,000 patients nationwide. I am an active Phase I investigator at UMGCC, with two NCI-funded studies in collaboration with Wayne State's U-01 for Phase I studies and numerous corporate Phase I studies. I also serve as the principal investigator (PI) of UMGCC's K12 Calabresi Scholar Clinical Oncology Training Program.
At the level of basic science, I continue to be active in understanding the molecular mechanism of action of novel anti-cancer agents through my collaborations with basic scientists. In particular, I have been privileged to collaborate with Dr. Averell Gnatt on my active Komen grant in the U Maryland Department of Pharmacology in refining our understanding of the mechanism of aryl hydrocarbon receptor (AhR) on cellular responses to aminoflavone(AF), continuing work that I began in the NIH intramural program where my group associated AF cytotoxicity with the capacity to engage AhR signaling. This application extends that work in a way that will have clinical applicability and mechanistic relevance to the function of the AhR in breast cancer.
Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004, 5:25-35.
Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther. 2004; 3111-21.
Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R,
Rubinstein L, Sausville EA, Vistica DT. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol.; 1:1688-97.
Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A. 2004;101(14):4821-6.
Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17 demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs. 2004 15:377-87.
Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, Venitz J, Figg WD, Sparreboom A. Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:289-94.
Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer. 2004;10:821-6.
Hollingshead MG, Bonomi CA, Borgel SD, Carter JP, Shoemaker R, Melillo G, Sausville EA. A potential role for imaging technology in anticancer efficacy evaluations. Eur J Cancer. 2004 40:890-8.
Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther. 2004 3:715-25.
Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cellcarcinoma: a potential target for UCN-01. Clin Cancer Res. 2004;10:4029-37.